GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%
Thu, 31 May

GLENMARK PHARMA has announced its results for the quarter ended March 2018. Here is a detailed performance review of the same:

GLENMARK PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Mar-17*
3
Dec-17*
3
Mar-18*
QoQ ChangeYoY Change
Net SalesRs m24,57222,03722,7983.5%-7.2%
Other incomeRs m513-23269635.6%
TurnoverRs m25,08521,80523,4947.7%-6.3%
ExpensesRs m20,13318,81019,5303.8%-3.0%
Gross profitRs m2,6033,2273,2681.3%25.6%
DepreciationRs m689754735-2.5%6.7%
InterestRs m6977057445.6%6.8%
Profit before taxRs m1,7301,5372,48561.7%43.6%
TaxRs m10748996897.9%802.7%
Profit after taxRs m1,6231,0471,51644.8%-6.6%
Gross profit margin%10.614.614.3
Effective tax rate%6.231.839.0
Net profit margin%6.54.86.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 7.2% on a year-on-year (YoY) basis. The expenses were down by 3.0% YoY during the same period.
  • The company's operating profit increased by 25.6% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 14.3% in 4QFY18 as against 10.6% in 4QFY17.
  • Depreciation charges and finance costs increased by 6.7% YoY and 6.8% YoY, respectively.
  • Other income increased by 35.6% YoY during the quarter.
  • Net profit for the quarter declined by 6.6% YoY. Net profit margins during the quarter declined from 6.5% in 4QFY17 to 6.5% in 4QFY18.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 3.5% on a quarter-on-quarter (QoQ) basis. The expenses were up by 3.8% QoQ during the same period.
  • The company's operating profit increased by 1.3% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 14.3% in 4QFY18 as against 14.6% in 3QFY17.
  • Net profit for the quarter increased by 44.8% QoQ, while net profit margins increased from 4.8% in 3QFY17 to 6.5% in 4QFY18.

To see how GLENMARK PHARMA has performed over the last eight quarters, please visit here.

GLENMARK PHARMA Share Price Performance

Over the last one year, GLENMARK PHARMA share price has moved up from Rs 636.5 to Rs 523.0, registering a Loss of Rs -113.5 or around 17.8%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,042.0 (down 0.5%). Over the last one year it has moved down from 13,563.8 to 13,042.0, a gain of -521.8 points (down 3.8%).

Overall, the S&P BSE SENSEX is up 0.5% over the year.

Current Valuations

At the current price of Rs 523.0, the price to earnings (P/E) ratio of GLENMARK PHARMA stands at 17.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.2 times.

Equitymaster requests your view! Post a comment on "GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%". Click here!

  

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


May 29, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - TEVA PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS